

What: Board of Directors Meeting
 Date & Time: Thursday, November 02, 2022; 2:00-4:00 p.m. (PT)
 Call in Number: Zoom Invite Below
 Location: Webinar/Teleconference
 Zoom Link: To register for the meeting, please review the [Public Comment Protocol](#) then email wvameetings@wavaccine.org at least two business days in advance of the meeting.

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

Agenda for Board of Directors Meeting

Approx. Time	Pg.	*	Topic/ Anticipated Action	Presented by:
2:00-2:05 p.m.			1. Welcome & Introductions a. Notification of Recording	J. Zell
2:05-2:15 p.m.	Pg. 4-8 Pg. 9 Pg. 9	* * *	2. Consent Calendar Items a. Board Meeting Minutes: June 15, 2023 & Sept. 28, 2023 b. Vote to Reappoint Members (Chea and Murphy) c. Votes to Elect Officers / Committee Chairs	J. Dunn
2:15-2:25 p.m.	Pg. 10-36 Pg. 37-53	* *	3. Financial Updates a. Current Financials b. Finance Committee Update i. Vote to Ratify 2022-23 Audited Financial Statements	P. Miller / J. Zell / J. Sobeck
2:25-3:05 p.m.	Pg. 54-62 Pg. 63-65 Pg. 66-67	* * *	4. ED / AD Updates a. Cash Reserves/Future Assessment Grid b. Off Cycle Vaccine Additions i. Vote to Add New Vaccines to Assessment Grid c. COVID Roll-out d. RSV/Statutory Update i. In-patient Hospital Assessments ii. Statute Update iii. Coalition Building e. Vote to Approve/Publish 2022-23 Annual Report	J. Zell / P. Miller M. Roberts / K. Kolan
3:05-3:15 p.m.			5. Department of Health Updates	M. Roberts / J. Sherls-Jones / J. Jorgenson
3:15-4:00 p.m.			6. Executive Session (public excluded)	

**WVA Meeting of the Board of Directors
November 2, 2023
Proposed Form of Votes**

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors. All Board policy and the final form of votes is exclusively the province of the Board acting collectively as the Board of Directors.

Items under Agenda Section 2:

- VOTED: To approve the minutes of the June 15, 2023 Board Meeting.
[To approve the minutes of the June 15, 2023 Board Meeting with the changes suggested at the meeting.]
- VOTED: To approve the minutes of the September 28, 2023 Board Meeting.
[To approve the minutes of the September 28, 2023 Board Meeting with the changes suggested at the meeting.]
- VOTED: To reappoint Dr. Chea as a Board Member pursuant to RCW 70.290.030 (3)(c) whose term expires in 2027.
- VOTED: To reappoint Mr. Murphy as a WVA Board member pursuant to RCW 70.290.030 (3)(a) whose term expires in 2027.
- VOTED: To approve the 2024 WVA officers and committee chairs as presented to the Board at the meeting.
[To approve the 2023 WVA officers and committee chairs as presented to the Board, with the changes suggested at the meeting.]
- VOTED: To approve the individuals listed to serve on the WVA's Finance, Operations, and Vaccine Committees for calendar year 2024 as presented to the Board at the meeting.
[To approve the individuals listed to serve on the WVA's Finance, Operations, and Vaccine Committees for calendar year 2024 with the changes suggested at the meeting.]

Items under Agenda Section 3:

- VOTED: To ratify the action of the Finance Committee in adopting and authorizing publication of the 2022-23 Financial Statements and Independent Auditor's Report.
[To ratify the action of the Finance Committee in adopting and authorizing publication of the 2022-23 Financial Statements and Independent Auditor's Report with the changes suggested at the meeting.]

Items under Agenda Section 4:

VOTED: To approve the addition of new, off-cycle ACIP approved vaccines to the WVA Assessment Grid when they are added to the Washington Childhood Vaccination Program as presented to the Board at the meeting.

[To approve the addition of new, off-cycle ACIP approved vaccines to the WVA Assessment Grid when they are added to the Washington Childhood Vaccination Program, with the changes suggested at the meeting.]

VOTED: To approve the 2022-23 WVA Annual Report as presented to the Board.

[To approve the 2022-23 WVA Annual Report with the changes suggested at the meeting.]

Items under Agenda Section 6:

VOTED: To approve additional RSV-related administrative expenses and delegate authority to the Executive Committee to finalize related agreements as presented.

[To approve additional RSV-related administrative expenses and delegate authority to the Executive Committee to finalize related agreements with the changes suggested at the meeting.]

**Washington Vaccine Association
Board of Directors Meeting
June 15, 2023; 2:00-3:30 p.m. (PT)**

I. Attendance. This meeting was conducted in person and virtually. Participating in all or part of the meeting were the following individuals:

<u>Directors</u>	<u>WVA</u>
John Dunn, MPH, MD, Kaiser Permanente, <i>Chair</i>	Julia Walter Zell, MA., Esq., Executive Director
Beth Harvey, MD, South Sound Pediatrics, <i>Vice Chair</i>	
Ed Marcuse, MD, MPH, FPIDS, University of Washington, <i>Secretary</i>	<u>Helms & Company, Inc.</u>
John Soback, MBA, MD, Regence Blue Shield, <i>Treasurer</i>	Patrick Miller, MPH, WVA, Administrative Director
(virtual)	Ashley Ithal, MPH, WVA, Program Support (virtual)
Helen Chea, MD, Molina (virtual)	Leslie Walker, CPA, Mason+Rich, PA (virtual)
Jason Farber, Esq., Davis Wright Tremaine LLP (virtual)	
Janel Jorgenson (for Michele Roberts), WA DOH	<u>Others</u>
Kara Manley, United Healthcare (virtual)	Anne Redman, Esq., Perkins Coie
Randy Parker, Northwest Carpenters Trust	Rick Hourigan, MD, Cigna (virtual)
Pamela Sheffield, MD, Aetna	Breelyn Young, GSK
	Brayson Rusinyak, Kasier, GSK
	Craig Sexton, GSK (virtual)

II. Summary of Actions Taken and/or Recommended

Actions Taken (votes adopted)

- i. To approve the minutes of the April 13, 2023, Board Meeting

III. Minutes

Welcome and Introductions

Dr. Dunn called the meeting to order at 2:02 p.m. Ms. Zell announced that the meeting would be recorded for the benefit of the minute taker, to be deleted once the minutes are approved. Ms. Young and Mr. Rusinyak introduced themselves to the Board.

Consent Calendar

Dr. Dunn asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously

VOTED: To approve the minutes of the April 13, 2023, Board Meeting.

IV. Financial Update

Financial Statements and Year End Cash Projections and Administrative Expenses

Mr. Miller briefly reviewed May 2023's, unaudited financial statements. Mr. Miller reported that as of the end of May, the WVA's administrative budget was ahead of budget by \$256,000 due primarily to lower legal fees and the deferral of the new hire and associated costs. Although Mr. Miller believes the WVA will continue to be ahead of budget by the end of June, there are expenses associated with the annual Grid mailings that will be accounted for.

Ms. Walker provided an update on the WVA's strong cash position, reporting that the WVA is \$2.6 million below the projected FY23 budget of \$46 million which she believes will hold through the end of the FY. Ms. Walker also noted that June is typically a month whereby cash outflows exceed receipts

FY 2023 Audit Preparation

Ms. Zell provided an update on the CliftonLarsonAllen LLP's (CLA) audit which is set to begin on July 1, 2023. The financial statements will be presented to the Finance Committee in September 2023 and to the Board in November

2023. Ms. Zell noted that next year's audit next will likely require additional review of the WVA information technology functions due to changes in the auditing standards. This will require adjustments to the FY2025 budget.

V. DOH Updates

Ms. Jorgenson reported that the Washington school immunization dashboard (<https://doh.wa.gov/data-and-statistical-reports/washington-tracking-network-wtn/school-immunization>) has been updated with more recent data; an update was sent to the WVA Vaccine Committee last week. Ms. Jorgenson noted that the data demonstrate that vaccination gaps exist in parts of the state and there continues to be a need for the WA Department of Health (DOH) to communicate to providers that children in those areas need to catch up on their immunizations. Ms. Jorgenson reported that an article has been submitted for publication in MMWR regarding vaccine exemptions and the impact on school vaccination rates in Washington. Initial data for the most recent school year are expected to be available in July.

The DOH is developing an IIS / Quality Scorecard for providers based on the COVID immunization rate scorecard. Ms. Jorgensen noted that the goal of this scorecard is to give providers a snapshot of the quality of their data, including completeness, meeting requirements, and HL7 rejections vs. acceptances, specifically.

Ms. Jorgenson noted changes to the [WA DOH Care-a-Van](#) program, noting a new partnership with the Seattle Storm called the "Take your shot! Initiative" whereby people who receive a vaccine through the program will receive tickets to a game. Further, the DOH is planning on providing routine adult vaccines through this program in the future. Programmatic funding may be a limiting factor.

Ms. Jorgenson reported that an internal state accounting audit of the Washington State Childhood Vaccine Program will start in July. Ms. Zell asked if the audit results would be provided to the WVA Board. Ms. Jorgenson will let Ms. Zell know.

Finally, Ms. Jorgenson noted that a bridge program is being created by the DOH to continue to provide COVID vaccines to those who are uninsured once commercialization occurs.

VI. ED/AD Updates

Monthly Board Reporting Update

Ms. Zell previewed the new proposed format for the AD ED report. The new format is designed to be more visual and improve readability. Additional summary information as well as an activity calendar were added; financial KPIs (demonstrating planned vs. actual cash, etc.) remain. The report was previously reviewed by the Executive Committee. Mr. Miller added that if Committee members had additional topics that they would like included, to share those requests and they will be added if data support it. Dr. Marcuse requested that the rationale behind the cash reserve position be added; there was a time when the organization had no funds and required a line of credit.

Stakeholder Relations Position Update

Ms. Zell provided an update on the stakeholder relations position. Two finalist candidates have been identified. The WVA is working with a human resources consultant to conduct references and prepare the offer letter for the final candidate.

Compliance Updates

Ms. Zell reported that the WVA continues to work on provider compliance issues. A provider attestation has been developed for use when the provider has multiple billing issues. The attestation states that the provider is fulfilling their WVA and DOH obligations. One organization has been asked to sign the attestation and it is currently under review by their counsel.

VII. Public Comments

No public comments.

VIII. Executive Session - Confidential.

IX. Closing

With no further business before the Board, Dr. Dunn closed the meeting at 3:30 PT.

Meeting Notes
WVA Special Purpose RSV Board Meeting
September 28, 2023; 12:00-2:00 p.m. PT

- I. Attendance.** This meeting was conducted in person and by webinar. Participating in all or part of the meeting were the following individuals:

Directors

John Dunn, MD, MPH, Kaiser Permanente, *Chair*
Beth Harvey, MD, South Sound Pediatrics, *Vice Chair* (virtual)
Ed Marcuse, MD, MPH, FPIDS, University of Washington, *Secretary*
John Sobeck, MD, MBA, Regence Blue Shield, *Treasurer* (virtual)
Pam Sheffield, MD, Aetna (virtual)
Jason Farber, Esq., Davis Wright Tremaine LLP (virtual)
Kara Manley, United (virtual)
Chad Murphy, PharmD, Premera (virtual)
Michele Roberts, Washington Department of Health (virtual)
Helen Chea, MD, Molina Healthcare (virtual)
Chad Murphy, Premera (virtual)

WVA

Julia Walter Zell, MA., Esq., Executive Director
Cheri Cagle, WVA Stakeholder Liaison (virtual)

Helms & Company, Inc.

Patrick Miller, MPH, WVA, Administrative Director
Ashley Ithal, MPH, WVA, Program Support
Leslie Walker, CPA, Mason+Rich, PA

Others

Jamilia Sherls-Jones, Washington Department of Health (virtual)
Megan Cichy, Washington Department of Health (virtual)
Janel Jorgenson, Washington Department of Health (virtual)
Kelly Cooper, Wash Washington Department of Health (virtual)
Sam Pskowski, Washington Department of Health (virtual)
Marina Martinez, Washington Chapter of the American Academy of Pediatrics (virtual)
Eric Sonju, Washington Attorney General's Office (virtual)
Kiran Griffith, Esq., Stoel Rives
Anne Redman, Esq., Perkins Coie (virtual)

II. Minutes

Welcome and Introductions

At 12:02 p.m. Ms. Zell called the meeting to order and announced that the meeting would be recorded for the benefit of the minute taker, to be deleted once the minutes are approved. At the beginning of the meeting Jason Farber notified the Chair and provided a chat note stating that he would abstain from action at the meeting including all votes, and confirmed his participation in discussion did not constitute his assent.

Ms. Zell, stating the need to begin quickly, skipped introductions and asked Ms. Roberts to review the Washington State Department of Health's (DOH) position on including nirsevimab in the state universal vaccine program, and the agency's request that the WVA fund it this RSV season in advance of express statutory language that would it to do so. Ms. Roberts outlined what the state's universal vaccine program provides for Washington: equitable access to vaccines regardless of insurance status; reduction in payer expenditures via U.S. Centers for Disease Control and Prevention (CDC) federal contract purchases (~ 30% savings); mitigation of financial, staffing, inventory, and related provider burdens due to a single vaccine stock in provider offices. Ms. Roberts acknowledged the Advisory Committee on Immunization Practices' (ACIP) immunization recommendations for nirsevimab are unique, as nirsevimab does not fall within WVA's statutory definition of "Vaccine" as it is technically a monoclonal antibody. She reported that the DOH will seek a technical, minor statutory change to align the state's definition with ACIP's," which would allow products such as nirsevimab to be added to the state universal vaccine program if recommended by ACIP and covered by VFC. Ms. Roberts concluded by stating that the Governor's Office has committed to support the statutory change to the WVA's enabling legislation.

Ms. Zell began by providing an overview of the summary of actions the WVA has taken since the ACIP voted to include nirsevimab in its routine immunization schedule, highlighting the Executive Committee meeting on 8/17/23, and the formal request from DOH to fund nirsevimab.

Ms. Zell called on Dr. Marcuse to provide a summary of WVA Vaccine Committee’s meeting and recommendations to the Board. Dr. Marcuse began by outlining the clinical efficacy of nirsevimab, which was recommended by the ACIP for inclusion on the CDC’s immunization schedule and the Vaccines for Children program. It is a monoclonal antibody providing passive immunization in infants and toddlers against RSV. Dr. Marcuse reviewed the role of the WVA and the Vaccine Committee in making recommendations on specific immunizations to fund via the state universal vaccine program. He noted that virtually all universally available vaccines have been listed on the CDC’s federal contract and are available under the program. He stated that nirsevimab presents a unique issue for the WVA in that it is not a vaccine that stimulates active immunity, but it is an antibody that confers passive immunity. Therefore, nirsevimab does not fit under the statutory definition of “Vaccine” in the WVA’s establishing statute. Dr. Marcuse discussed the importance of obtaining consultation from third-party, non-board member experts to inform the WVA Vaccine Committee’s deliberations and recommendations. In that vein, he invited Dr. Amy Carter, Allegro Pediatrics, and Dr. Frank Bell, Swedish Health Services, to join a special session of the WVA Vaccine Committee on September 21, 2023, to provide an overview of the clinical importance of nirsevimab. Dr. Marcuse and Ms. Zell each highlighted recommendations from the WVA Vaccine Committee for the Board to consider in its executive session at today’s meeting.

Ms. Zell proposed the group move into executive session. Ms. Roberts requested that Dr. Sherls-Jones, Mr. Sonju and Ms. Jorgenson join her on behalf of the WA DOH.

III. Public Comments – No public comments.

IV. Executive Session – Confidential.

V. Closing

The meeting was adjourned at 2:03 p.m. PT.

**WVA Board of Directors, Board Terms,
Corporate Officers, and Committees
(Approved by the WVA Board November 2, 2023)**

The following individuals are voting members of WVA under RCW 70.290.010--090 (Wash. 2010) (the “Act”).
Their respective terms and committee assignments are set out below.

Name	Organization	Statutory Authority RCW 70.290.030	Year Term Ends	Officers	Executive Committee	Finance Committee	Operations Committee†	Vaccine Committee RCW 70.290.050
Murphy, Chad	Premiera BlueCross	Sec. (3)(a) Four Members	2026		C			X
Dunn, John	Kaiser Permanente	Sec. (3)(b) 1 Member	2026	Board Chair				X
Farber, Jason	Davis Wright Tremaine	Sec. (3)(c) 1 Member	2026			X		
Manley, Kara	UnitedHealthcare	Sec. (3)(a) Four Members	2025				X	
Harvey, Beth	South Sound Pediatrics	Sec. (3)(f) 2 Members Secretary Appointment	2026	Board Vice President	X			
Vacant	Northwest Carpenters Trust	Sec. (3)(d) 1 Member Secretary Appointment	2026					
Marcuse, Ed	University of Washington	Sec. (3)(f) 2 Members Secretary Appointment	2024	Board Secretary	X			C
Roberts, Michele	Department of Health	Sec. (3)(g) Secretary Designee	•					Sherls-Jones, Jamilia (alternate)
Sobeck, John	Regence BlueShield	Sec. (3)(a) Four Members	2025	Board Treasurer	X	C		
Sheffield, Pam	Aetna	Sec. (3)(a) Four Members	2027				X	
Chea, Helen	Molina	Sec. (3)(c) 1 Member	2026			X		

Legend:

(“C”)=Chairperson

(“X”)=Member


(“•”)=Serves until a successor is appointed by the Secretary

(“†”)=Chaired by Executive Director


WASHINGTON VACCINE ASSOCIATION
UNAUDITED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED
September 30, 2023
With Supplemental Informational Reporting

Prepared by
Helms & Company, Inc., Administrator


Cash Balances Beginning and End of Period September 2022 - September 2023



Total Vaccine Collections and Vaccine Remittances to State of WA September 2022 - September 2023



Investment Income / (Loss) September 2022 - September 2023



Washington Vaccine Association
Statement of Cash Flows
For the Periods Ended

	Month 9/30/2022	Month 10/31/2022	Month 11/30/2022	Month 12/31/2022	Month 1/31/2023	Month 2/28/2023	Month 3/31/2023	Month 4/30/2023	Month 5/31/2023	Month 6/30/2023	Month 7/31/2023	Month 8/31/2023	Month 9/30/2023	13 Month Average
1 Cash balance - beginning	\$ 49,802,160	\$ 45,521,419	\$ 45,226,880	\$ 47,391,252	\$ 49,581,422	\$ 48,745,241	\$ 48,158,103	\$ 47,367,244	\$ 46,396,888	\$ 45,037,740	\$ 44,528,984	\$ 42,178,691	\$ 39,591,640	46,117,512.67
Inflows:														
2 Vaccine collections	7,154,302	6,593,300	7,182,396	7,262,565	5,077,451	5,644,933	6,380,230	5,331,261	5,526,126	7,218,720	6,483,475	8,281,002	4,800,462	6,601,586.94
3 Interest income - payers														-
4 Investment income/ (loss)	(522,104)	(80,250)	292,475	159,984	299,489	(182,504)	407,515	153,609	(32,483)	49,646	174,956	124,168	52,184	41,812.54
5 Total inflows	6,632,198	6,513,050	7,474,871	7,422,549	5,376,940	5,462,429	6,787,745	5,484,870	5,493,643	7,268,366	6,658,431	8,405,170	4,852,646	\$ 6,643,399
Outflows:														
Program														
6 Vaccine remittance State of WA	(10,771,706)	(6,666,286)	(5,171,147)	(5,116,478)	(6,069,523)	(5,932,158)	(7,397,831)	(6,320,084)	(6,725,775)	(7,626,289)	(8,866,194)	(10,790,790)	(14,891,373)	(7,872,741.07)
Administration														
7 Direct Processing Costs	(83,479)	(88,260)	(100,373)	(73,539)	(95,734)	(87,212)	(87,995)	(87,008)	(86,000)	(90,978)	(88,976)	(88,911)	(90,982)	(88,149.77)
8 Executive Director Costs and Support Fees	(24,988)	(28,476)	(24,102)	(28,179)	(22,890)	(20,416)	(64,409)	(29,651)	(24,217)	(28,932)	(33,502)	(28,227)	(46,134)	(29,230.39)
9 Provider and Payer Education and Outreach	-	-	(7,279)	(597)	(40)	(4,868)	(5,238)	(9,905)	(11,202)	(24,221)	(4,418)	(19,974)	(2,279)	(6,749.35)
10 Administrative Costs	(29,166)	(20,967)	(3,998)	(9,986)	(21,334)	(1,133)	(19,351)	(4,798)	(1,817)	(2,922)	(10,234)	(60,539)	(88,408)	(19,183.44)
11 Other Discretionary Expenditures	(3,600)	(3,600)	(3,600)	(3,601)	(3,600)	(3,780)	(3,780)	(3,780)	(3,780)	(3,780)	(5,400)	(3,780)	(3,780)	(4,237.00)
12 Total Administration	(141,233)	(141,303)	(139,352)	(115,901)	(143,598)	(117,409)	(180,773)	(135,142)	(127,016)	(150,833)	(142,530)	(201,431)	(231,583)	(147,550)
13 Net all other outflows	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14 Total outflows	(10,912,939)	(6,807,589)	(5,310,499)	(5,232,379)	(6,213,121)	(6,049,567)	(7,578,604)	(6,455,226)	(6,852,791)	(7,777,122)	(9,008,724)	(10,992,221)	(15,122,956)	(8,020,291.03)
15 Net Cash Incr (decr) for period	(4,280,741)	(294,539)	2,164,372	2,190,170	(836,181)	(587,138)	(790,859)	(970,356)	(1,359,148)	(508,756)	(2,350,293)	(2,587,051)	(10,270,310)	(1,376,892)
16 Cash balance - end of period	\$ 45,521,419	\$ 45,226,880	\$ 47,391,252	\$ 49,581,422	\$ 48,745,241	\$ 48,158,103	\$ 47,367,244	\$ 46,396,888	\$ 45,037,740	\$ 44,528,984	\$ 42,178,691	\$ 39,591,640	\$ 29,321,330	\$ 44,740,621

Note: Cash balance includes amounts in KeyBank and Morgan Stanley

Washington Vaccine Association
Statement of Financial Position
As of September 30, 2023

ASSETS

1	Current Assets		
2	Cash and Cash Equivalents	\$	945,430
3	Accounts Receivable		-
4	Investments		28,375,900
5	Members Estimated Collectible Assessments		12,002,781
6	Prepaid Vaccine		10,572,664
7	Prepaid Administrative Services		-
8	Total Current Assets		<u>51,896,775</u>
9	Total Assets	\$	<u><u>51,896,775</u></u>

LIABILITIES AND NET ASSETS

10	Current Liabilities		
11	Accounts Payable	\$	144,540
12	Other Accruals		13,432
13	Total Current Liabilities		<u>157,972</u>
14	Assessments Collected in Excess of Vaccine Funding and Administrative Activities		<u>51,738,803</u>
15	Total Liabilities		<u>51,896,775</u>
16	Total Liabilities and Net Assets	\$	<u><u>51,896,775</u></u>

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

		Month Ended September 30, 2023			For Three Months Ended September 30, 2023		
		A	B	C	D	E	F
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
		Revenues / Vaccine Expenses					
1	Assessment Activity:						
2	Assessments	\$ (229,690)	\$ 7,091,946	\$ 6,862,256	\$ (1,638,436)	\$ 23,563,309	\$ 21,924,873
3	Recoveries	-	-	-	-	-	-
4	Estimated Over (Under) Collections	-	-	-	-	-	-
5	Refunds	(1,322,492)	-	(1,322,492)	(1,353,415)	-	(1,353,415)
6	Estimated 2% Waste	(110,165)	-	(110,165)	(272,263)	-	(272,263)
7	Estimated Price Variance and 3% Denial	(185,672)	-	(185,672)	(435,713)	-	(435,713)
8	DOH Replenishment	-	(7,087,289)	(7,087,289)	-	(22,608,407)	(22,608,407)
9	Adjustment to Correct Inventory	-	-	-	-	-	-
10	DOH Cost Recovery Admin Charge	(128,849)	-	(128,849)	(291,518)	-	(291,518)
11	Interest Income on Assessments	-	-	-	-	-	-
12	Net Assessment Activity	(1,976,868)	4,657	(1,972,211)	(3,991,346)	954,902	(3,036,444)
13	Investment Activity:						
14	Interest and Dividend Income - Morgan Stanley	87,344	-	87,344	248,346	-	248,346
15	Realized Gain/(Loss) on Investments - Morgan Stanley	(106,590)	-	(106,590)	(207,199)	-	(207,199)
16	Unrealized Gain/(Loss) on Investments - Morgan Stanley	73,143	-	73,143	304,785	-	304,785
17	Investment Management Expenses	(7,618)	-	(7,618)	(26,090)	-	(26,090)
18	Interest Income - KeyBank	5,905	-	5,905	31,466	-	31,466
19	Net Investment Activity	52,184	-	52,184	351,308	-	351,308
20	Net Revenues	(1,924,684)	4,657	(1,920,027)	(3,640,038)	954,902	(2,685,136)

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

	A	B	C	D	E	F
	Month Ended September 30, 2023			For Three Months Ended September 30, 2023		
	Administrative	Vaccine	Total	Administrative	Vaccine	Total
	Other Expenses					
21 Administrative Expenses:						
22 Direct Processing Costs						
23 Administrator (Helms & Company, Inc.)	65,432	-	65,432	196,296	-	196,296
24 EDI /ACH Clearinghouse Maintenance (Helms & Company, Inc.)	3,750	-	3,750	16,137	-	16,137
25 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	7,150	-	7,150	17,442	-	17,442
26 Lockbox and Bank Fees	4,309	-	4,309	11,994	-	11,994
27 Recovery and Compliance (Helms & Company, Inc.)	5,250	-	5,250	15,750	-	15,750
28 Lockbox Intake (OrboGraph)	5,091	-	5,091	11,250	-	11,250
29 Total Direct Processing Costs	90,982	-	90,982	268,869	-	268,869
30 Executive Director Costs and Related Support Fees						
31 Executive Director Salary	26,306	-	26,306	65,383	-	65,383
32 Payroll Taxes	962	-	962	1,587	-	1,587
33 Leased Employee per Check Fee	116	-	116	348	-	348
34 Executive Director Travel and Lodging, Education, and Other	4,666	-	4,666	24,127	-	24,127
35 Technology Support (Desktop and Telephony)	415	-	415	2,748	-	2,748
36 Total Executive Director Costs and Related Support Fees	32,464	-	32,464	94,193	-	94,193
37 Provider and Payer Education and Outreach						
38 Provider Education Materials, Development and Printing	-	-	-	10,608	-	10,608
39 Postage	-	-	-	14	-	14
40 Website and Information Technology	11,850	-	11,850	11,850	-	11,850
41 Technical Consultants	-	-	-	-	-	-
42 Provider Office Training Sessions	862	-	862	8,666	-	8,666
43 Advertising and Sponsorships	-	-	-	-	-	-
44 Hospitality	1,417	-	1,417	-	-	-
45 Provider Services Rep	-	-	-	7,384	-	7,384
46 Leased Employee per Check Fee	139	-	139	139	-	139
47 Total Provider and Payer Education and Outreach	14,268	-	14,268	38,660	-	38,660
48 Administrative Costs						
49 Legal Counsel	11,533	-	11,533	11,533	-	11,533
50 Operations/Compliance/IT - Compliance Program Expansion	17,549	-	17,549	17,549	-	17,549
51 Communications - Graphic Designer; Printing; Postage	-	-	-	-	-	-
52 Audit Fees	20,333	-	20,333	24,733	-	24,733
53 Audit Fees Segmentation of Accounts; Settlement Reporting	2,844	-	2,844	2,844	-	2,844
54 Government Relations, Including Travel, Meals, and Consultants	-	-	-	-	-	-
55 Government Relations - Federal and State; Coordination with Parties	-	-	-	-	-	-
56 Registered Agent Fee	-	-	-	-	-	-
57 Bank Fees	-	-	-	-	-	-
58 Office Supplies and Equipment	3,259	-	3,259	4,659	-	4,659
59 Rent, ELM and Storage Facility	-	-	-	267	-	267
60 Other Admin Support Provided by Lessor	-	-	-	-	-	-
61 Board Retreat and Meetings	-	-	-	-	-	-
62 Insurance	-	-	-	-	-	-

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

		A	B	C	D	E	F
		Month Ended September 30, 2023			For Three Months Ended September 30, 2023		
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
63	Cyber Liability	-	-	-	28,932	-	28,932
64	Directors and Officers	-	-	-	21,740	-	21,740
65	General Liability	-	-	-	1,669	-	1,669
66	Insurance - Other	-	-	-	-	-	-
67	Legal - Special Projects and L	-	-	-	2,700	-	2,700
68	Legal - Contracting; Counsel; Meetings; Interpretation; Consultation	34,571	-	34,571	34,571	-	34,571
69	Total Administrative Costs	90,089	-	90,089	91,852	-	149,516
70	Other Discretionary Expenditures						
71	Executive Director and Other Contractor Bonus	-	-	-	-	-	-
72	Human Resources and Governance	3,780	-	3,780	12,960	-	12,960
73	Total Other Discretionary Expenditures	3,780	-	3,780	12,960	-	12,960
74	Total Administrative Expenses	231,583	-	231,583	508,215	-	565,879
75	Total Change in Unrestricted Net Assets	\$ (2,156,267)	\$ 4,657	\$ (2,151,610)	\$ (4,148,253)	\$ 954,902	\$ (3,251,015)

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

	A	B	C	D	E	F
	Month Ended September 30, 2023			Month Ended September 30, 2022		
	Administrative	Vaccine	Total	Administrative	Vaccine	Total
	Revenues / Vaccine Expenses					
1 Assessment Activity:						
2 Assessments	\$ (229,690)	\$ 7,091,946	\$ 6,862,256	\$ (761,410)	\$ 7,952,248	\$ 7,190,838
3 Recoveries	-	-	-	-	-	-
4 Estimated Over (Under) Collections	-	-	-	-	-	-
5 Refunds	(1,322,492)	-	(1,322,492)	(24,853)	-	(24,853)
6 Estimated 2% Waste	(110,165)	-	(110,165)	(95,463)	-	(95,463)
7 Estimated Price Variance and 3% Denial	(185,672)	-	(185,672)	(11,684)	-	(11,684)
8 DOH Replenishment	-	(7,087,289)	(7,087,289)	-	(8,515,253)	(8,515,253)
9 Adjustment to Correct Inventory	-	-	-	-	-	-
10 DOH Cost Recovery Admin Charge	(128,849)	-	(128,849)	(85,788)	-	(85,788)
11 Interest Income on Assessments	-	-	-	-	-	-
12 Net Assessment Activity	(1,976,868)	4,657	(1,972,211)	(979,197)	(563,005)	(1,542,202)
13 Investment Activity:						
14 Interest and Dividend Income - Morgan Stanley	87,344	-	87,344	94,913	-	94,913
15 Realized Gain/(Loss) on Investments - Morgan Stanley	(106,590)	-	(106,590)	(2,919)	-	(2,919)
16 Unrealized Gain/(Loss) on Investments - Morgan Stanley	73,143	-	73,143	(619,175)	-	(619,175)
17 Investment Management Expenses	(7,618)	-	(7,618)	(10,384)	-	(10,384)
18 Interest Income - KeyBank	5,905	-	5,905	15,460	-	15,460
19 Net Investment Activity	52,184	-	52,184	(522,104)	-	(522,104)
20 Net Revenues	(1,924,684)	4,657	(1,920,027)	(1,501,301)	(563,005)	(2,064,306)

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

	A	B	C	D	E	F
	Month Ended September 30, 2023			Month Ended September 30, 2022		
	Administrative	Vaccine Other Expenses	Total	Administrative	Vaccine	Total
21 Administrative Expenses:						
22 Direct Processing Costs						
23 Administrator (Helms & Company, Inc.)	65,432	-	65,432	65,432	-	65,432
24 EDI /ACH Clearinghouse Maintenance (Helms & Company, Inc.)	5,091	-	5,091	3,754	-	3,754
25 Clearinghouse Intake Processing (Availity, Zelis, Etc.)	7,150	-	7,150	6,226	-	6,226
26 Lockbox and Bank Fees	4,309	-	4,309	3,766	-	3,766
27 Recovery and Compliance (Helms & Company, Inc.)	5,250	-	5,250	5,250	-	5,250
28 Lockbox Intake (RMS)	3,750	-	3,750	3,750	-	3,750
29 Total Direct Processing Costs	90,982	-	90,982	88,178	-	88,178
30 Executive Director Costs and Related Support Fees						
31 Salaries	26,306	-	26,306	18,810	-	18,810
32 Payroll Taxes	962	-	962	438	-	438
33 Leased Employee per Check Fee	116	-	116	195	-	195
34 Executive Director Travel and Lodging, Education, and Other	4,666	-	4,666	6,158	-	6,158
35 Technology Support (Desktop and Telephony)	415	-	415	335	-	335
36 Total Executive Director Costs and Related Support Fees	46,134	-	46,134	25,937	-	25,937
37 Provider and Payer Education and Outreach						
38 Education Materials Design, Development and Printing	-	-	-	-	-	-
39 Postage	-	-	-	-	-	-
40 Website and Information Technology	11,850	-	11,850	-	-	-
41 Technical Consultants	-	-	-	-	-	-
42 Provider Office Training Sessions	862	-	862	-	-	-
43 Advertising and Sponsorships	-	-	-	-	-	-
44 Hospitality	1,417	-	1,417	-	-	-
45 Provider Services Rep	-	-	-	-	-	-
46 Leased Employee per Check Fee	139	-	139	-	-	-
47 Total Provider and Payer Education and Outreach	2,279	-	2,279	-	-	-
48 Administrative Costs						
49 Legal Counsel	11,533	-	11,533	-	-	-
50 Operations/Compliance/IT - Compliance Program Expansion	17,549	-	17,549			
51 Communications - Graphic Designer; Printing; Postage	-	-	-			
50 Audit Fees	20,333	-	20,333	17,640	-	17,640
51 Audit Fees Segmentation of Accounts; Settlement Reporting	2,844	-	2,844			
51 Government Relations, Including Travel, Meals, and Consultants	-	-	-	-	-	-
52 Government Relations - Federal and State; Coordination with Parties	-	-	-			
52 Registered Agent Fee	-	-	-	-	-	-
53 Office Supplies and Equipment	3,259	-	3,259	126	-	126
54 Rent, ELM and Storage Facility	-	-	-	-	-	-
55 Other Admin Support Provided by Lessor	-	-	-	-	-	-

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

		A	B	C	D	E	F
		Month Ended September 30, 2023			Month Ended September 30, 2022		
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
56	Board Retreat and Meetings	-	-	-	-	-	-
57	Insurance						
58	Cyber Liability	-	-	-	-	-	-
59	Directors and Officers	-	-	-	-	-	-
60	General Liability	-	-	-	1,534	-	1,534
61	Insurance - Other	-	-	-	-	-	-
62	Legal - Special Projects and L	-	-	-	-	-	-
63	Legal - Contracting; Counsel; Meetings; Interpretation; Consultation	34,571	-	34,571			
63	Total Administrative Costs	33,444	-	68,015	19,300	-	19,300
64	Other Discretionary Expenditures						
65	Executive Director and Other Contractor Bonus	-	-	-	-	-	-
66	Human Resources and Governance	3,780	-	3,780	3,600	-	3,600
67	Total Other Discretionary Expenditures	3,780	-	3,780	3,600	-	3,600
68	Total Administrative Expenses	176,619	-	211,190	137,015	-	137,015
69	Total Change in Unrestricted Net Assets	\$ (2,101,303)	\$ 4,657	\$ (2,131,217)	\$ (1,638,316)	\$ (563,005)	\$ (2,201,321)

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

		For Three Months Ended September 30, 2023			For Three Months Ended September 30, 2022		
		A	B	C	D	E	F
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
		Revenues / Vaccine Expenses					
1	Assessment Activity:						
2	Assessments	\$ (1,638,436)	\$ 23,563,309	\$ 21,924,873	\$ (2,141,168)	\$ 22,357,331	\$ 20,216,163
3	Recoveries	-	-	-	-	-	-
4	Estimated Over (Under) Collections	-	-	-	-	-	-
5	Refunds	(1,353,415)	-	(1,353,415)	(67,596)	-	(67,596)
6	Estimated 2% Waste	(272,263)	-	(272,263)	(234,174)	-	(234,174)
7	Estimated Price Variance and 3% Denial	(435,713)	-	(435,713)	(32,342)	-	(32,342)
8	DOH Replenishment	-	(22,608,407)	(22,608,407)	-	(24,018,041)	(24,018,041)
9	Adjustment to Correct Inventory	-	-	-	-	-	-
10	DOH Cost Recovery Admin Charge	(291,518)	-	(291,518)	(246,145)	-	(246,145)
11	Interest Income on Assessments	-	-	-	-	-	-
12	Net Assessment Activity	(3,991,346)	954,902	(3,036,444)	(2,721,425)	(1,660,710)	(4,382,135)
13	Investment Activity:						
14	Interest and Dividend Income - Morgan Stanley	248,346	-	248,346	221,890	-	221,890
15	Realized Gain/(Loss) on Investments - Morgan Stanley	(207,199)	-	(207,199)	(2,919)	-	(2,919)
16	Unrealized Gain/(Loss) on Investments - Morgan Stanley	304,785	-	304,785	(867,732)	-	(867,732)
17	Investment Management Expenses	(26,090)	-	(26,090)	(32,076)	-	(32,076)
18	Interest Income - KeyBank	31,466	-	31,466	38,914	-	38,914
19	Net Investment Activity	351,308	-	351,308	(641,923)	-	(641,923)
20	Net Revenues	(3,640,038)	954,902	(2,685,136)	(3,363,347)	(1,660,710)	(5,024,058)

**Washington Vaccine Association
Statement of Activities and Changes in Net Assets**

	A	B	C	D	E	F
	For Three Months Ended September 30, 2023			For Three Months Ended September 30, 2022		
	Administrative	Vaccine Other Expenses	Total	Administrative	Vaccine	Total
21 Administrative Expenses:						
22 Direct Processing Costs						
23 Administrator (Helms & Company, Inc.)	196,296	-	196,296	203,796	-	203,796
24 EDI /ACH Clearinghouse Maintenance (Helms & Con	16,137	-	16,137	12,921	-	12,921
25 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	17,442	-	17,442	15,213	-	15,213
26 Lockbox and Bank Fees	11,994	-	11,994	10,876	-	10,876
27 Recovery and Compliance (Helms & Company, Inc.)	15,750	-	15,750	15,750	-	15,750
28 Lockbox Intake (OrboGraph)	11,250	-	11,250	3,750	-	3,750
29 Total Direct Processing Costs	268,869	-	268,869	262,306	-	262,306
30 Executive Director Costs and Related Support Fees						
31 Executive Director Salary	65,383	-	65,383	55,231	-	55,231
32 Payroll Taxes	1,587	-	1,587	1,933	-	1,933
33 Leased Employee per Check Fee	348	-	348	585	-	585
34 Executive Director Travel and Lodging, Education, an	24,127	-	24,127	10,482	-	10,482
35 Technology Support (Desktop and Telephony)	2,748	-	2,748	1,005	-	1,005
36 Total Executive Director Costs and Related Support Fees	94,193	-	94,193	69,236	-	69,236
37 Provider and Payer Education and Outreach						
38 Provider Education Materials, Development and Print	10,608	-	10,608	-	-	-
39 Postage	14	-	14	-	-	-
40 Website and Information Technology	11,850	-	11,850	-	-	-
41 Technical Consultants	-	-	-	-	-	-
42 Provider Office Training Sessions	8,666	-	8,666	-	-	-
43 Advertising and Sponsorships	-	-	-	-	-	-
44 Hospitality	7,384	-	7,384	-	-	-
45 Provider Services Rep	-	-	-	-	-	-
46 Leased Employee per Check Fee	139	-	139	-	-	-
47 Total Provider and Payer Education and Outreach	38,660	-	38,660	-	-	-
48 Administrative Costs						
49 Legal Counsel	11,533	-	11,533	8,128	-	8,128
50 Operations/Compliance/IT - Compliance Program E	17,549	-	17,549			
51 Communications - Graphic Designer; Printing; Posta	-	-	-			
52 Audit Fees	24,733	-	24,733	20,475	-	20,475
53 Audit Fees Segmentation of Accounts; Settlement R	2,844	-	2,844			
54 Government Relations, Including Travel, Meals, and	-	-	-	-	-	-
55 Government Relations - Federal and State; Coordina	-	-	-			
55 Registered Agent Fee	-	-	-	-	-	-

Unaudited - For Management Purposes - See Attached Notes
Prepared by Helms And Company, Inc.

Meeting Packet Page 21

Page 12

Washington Vaccine Association
Statement of Activities and Changes in Net Assets

		A	B	C	D	E	F
		For Three Months Ended September 30, 2023			For Three Months Ended September 30, 2022		
		Administrative	Vaccine	Total	Administrative	Vaccine	Total
56	Bank Fees	-	-	-	-	-	-
57	Office Supplies and Equipment	4,659	-	4,659	4,819	-	4,819
58	Rent, ELM and Storage Facility	267	-	267	-	-	-
59	Other Admin Support Provided by Lessor	-	-	-	-	-	-
60	Board Retreat and Meetings	-	-	-	-	-	-
61	Insurance						
62	Cyber Liability	28,932	-	28,932	-	-	-
63	Directors and Officers	21,740	-	21,740	52,058	-	52,058
64	General Liability	1,669	-	1,669	1,534	-	1,534
65	Insurance - Other	-	-	-	-	-	-
66	Legal - Special Projects and L	2,700	-	2,700	-	-	-
67	Legal - Contracting; Counsel; Meetings; Interpretatic	34,571	-	34,571	20,393	-	20,393
67	Total Administrative Costs	151,197	-	151,197	87,014	-	87,014
68	Other Discretionary Expenditures						
69	Executive Director and Other Contractor Bonus	-	-	-	-	-	-
70	Human Resources and Governance	12,960	-	12,960	16,200	-	16,200
72	Total Administrative Expenses	565,879	-	565,879	434,757	-	434,757
73	Total Change in Unrestricted Net Assets	\$ (4,205,917)	\$ 954,902	\$ (3,251,015)	\$ (3,798,104)	\$ (1,660,710)	\$ (5,458,814)

**Washington Vaccine Association
Administrative Budget Status
For Month of September 30, 2023**

	A Approved Budget	B Actual September 30, 2023	C Budget Variance
1 Direct Processing Costs			
2 Administrator (Helms & Company, Inc.)	65,432	65,432	-
3 EDI /ACH Clearinghouse Maintenance (Helms & Company, Inc.)	3,750	3,750	-
4 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	5,750	7,150	(1,400)
5 Lockbox and Bank Fees	4,000	4,309	(309)
6 Recovery and Compliance (Helms & Company, Inc.)	5,250	5,250	-
7 Lockbox Intake (RMS)	6,920	5,091	1,829
8 Total Direct Processing Costs	91,102	90,982	120
9 Executive Director Costs and Related Support Fees			
10 Salaries	25,212	25,706	(494)
11 Payroll Taxes	1,975	962	1,013
13 Benefit Stipend	600	600	-
12 Leased Employee per Check Fee	116	116	0
13 Executive Director Travel and Lodging, Education, and Other	6,500	4,666	1,834
14 Technology Support (Desktop and Telephony)	670	415	255
15 Total Executive Director Costs and Related Support Fees	35,073	32,464	2,609
16 Provider and Payer Education and Outreach			
17 Education Materials Design, Development and Printing	6,250	-	6,250
18 Postage	1,250	-	1,250
19 Website and Information Technology	1,250	11,850	(10,600)
20 Technical Consultants	1,500		1,500
21 Provider Office Training Sessions	1,500	862	638
22 Advertising and Sponsorships	167	-	167
23 Hospitality	300	1,417	(1,117)
24 Leased Employee per Check Fee	116	139	(23)
25 Total Provider and Payer Education and Outreach	12,333	14,268	(1,935)
26 Administrative Costs			
27 Legal - General Counsel and Governance	4,240	11,533	(7,293)
28 Audit Fees	30,377	20,333	10,044
29 Government Relations Consultants	417	-	417
30 Registered Agent Fee	-	-	-
31 Investment Management Fees	10,500	7,618	2,882
32 Office Supplies and Equipment	600	3,259	(2,659)
33 Rent	-	-	-
34 Other Admin Support Provided by Lessor	42	-	42
35 Board Retreat and Meetings	1,000	-	1,000
36 Insurance			
37 Cyber Liability	-	-	-
38 Directors and Officers	57,820	-	57,820
39 General Liability	1,687	-	1,687
40 Legal - Special Projects and Litigation	6,000	-	6,000
41 Total Administrative Costs	112,683	42,743	69,940
42 Other Discretionary Expenditures			
43 Executive Director Bonus Pool	-	-	-
44 Human Resources and Governance	4,350	3,780	570
45 Total Other Discretionary Expenditures	4,350	3,780	570
46 Total Budget	\$ 255,541	\$ 184,237	\$ 71,304

**Washington Vaccine Association
Administrative Budget Status
For Three Months Ended September 30, 2023**

	A Approved Budget	B Actual September 30, 2023	C Budget Variance
1 Direct Processing Costs			
2 Administrator (Helms & Company, Inc.)	196,296	196,296	-
3 EDI /ACH Clearinghouse Maintenance (Helms & Company, Inc.)	11,250	11,250	-
4 Clearinghouse Intake Processing (Avality, Zelis, Etc.)	17,250	17,442	(192)
5 Lockbox and Bank Fees	12,000	11,994	6
6 Recovery and Compliance (Helms & Company, Inc.)	15,750	15,750	-
7 Lockbox Intake (OrboGraph)	20,760	16,137	4,623
8 Total Direct Processing Costs	273,306	268,869	4,437
9 Executive Director Costs and Related Support Fees			
10 Salaries	75,636	63,583	12,053
11 Payroll Taxes	5,925	1,587	4,338
12 Benefit Stipend	1,800	1,800	-
13 Leased Employee per Check Fee	348	348	-
14 Executive Director Travel and Lodging, Education, and Other	19,500	24,127	(4,627)
15 Technology Support (Desktop and Telephony)	2,010	2,748	(738)
Total Executive Director Costs and Related Support Fees	105,219	94,193	11,026
16			
17 Provider and Payer Education and Outreach			
18 Provider Education Materials, Development and Printing	18,750	10,608	8,142
19 Postage	3,750	14	3,736
20 Website and Information Technology	3,750	11,850	(8,100)
21 Technical Consultants	4,500	-	4,500
22 Provider Office Training Sessions	4,500	8,666	(4,166)
23 Advertising and Sponsorships	501	-	501
24 Hospitality	900	7,384	(6,484)
25 Leased Employee per Check Fee	348	139	209
26 Total Provider and Payer Education and Outreach	36,999	38,660	(1,661)
27 Administrative Costs			
28 Legal - General Counsel and Governance	12,720	11,533	1,187
29 Audit Fees	30,377	24,733	5,644
30 Government Relations Consultants	1,251	-	1,251
31 Registered Agent Fee	150	-	150
32 Investment Management Fees	31,500	26,090	5,410
33 Office Supplies and Equipment	1,800	4,659	(2,859)
34 Rent	-	267	(267)
35 Other Admin Support Provided by Lessor	126	-	126
36 Board Retreat and Meetings	3,000	-	3,000
37 Insurance	-	-	-
38 Cyber Liability	22,800	28,932	(6,132)
39 Directors and Officers	57,820	21,740	36,080
40 General Liability	1,687	1,669	18
41 Legal - Special Projects and Litigation	18,000	2,700	15,300
42 Total Administrative Costs	181,231	122,323	58,908
43 Other Discretionary Expenditures			
44 Executive Director Bonus Pool	-	-	-
45 Human Resources and Governance	13,050	12,960	90
46 Total Other Discretionary Expenditures	13,050	12,960	90
47 Total Budget	\$ 609,805	\$ 537,005	\$ 72,800

**Washington Vaccine Association
Administrative Budget Status
For Three Months Ended September 30, 2023**

		A	B	C
		Approved	Actual	Budget
		Budget	September 30, 2023	Variance
1	Legal - Contracting; Counsel; Meetings; Interpretation; Consultation	75,000	34,571	40,429
2	Government Relations - Federal and State; Coordination with Parties; Lobbying	35,000	-	35,000
3	Finance/Audit - Segmentation of Accounts; Settlement Reporting; Collections	50,000	2,844	47,156
4	Operations/Compliance/IT - Compliance Program Expansion; Recovery Management	55,000	17,549	37,451
5	Communications - Graphic Designer; Printing; Postage; Mailing Services	35,000	-	35,000
6	Total Budget	\$ 250,000	\$ 20,393	\$ 229,607

Washington Vaccine Association

Notes to Financial Statements

For the Month Ended September 30, 2023

Balance Sheet

Lines 2 and 4. Cash decreased in September by approximately \$10,270,000. Total cash and investments at month end are approximately \$29 million as compared to the budgeted cash position of \$32 million. The time-lag between the date of service and the receipt of payment has been considered when projecting cash reserves for FY2023.

Line 6. The Prepaid Vaccine amount includes the amount requested by the Washington Department of Health (DOH) for the October 2023 replenishment of vaccines. The amount includes the administrative fee of 1.4% which equaled \$203,822 included in the request.

Line 5. Members Estimated Collectible Assessments reflects the value of vaccine funding provided to the DOH for the purchase of vaccines for which the Association expects to receive an assessment payment.

Line 12. In January of 2023 we requested that a payer turn offsets off on our account and formally request refunds for denied claims rather than offsetting the denials against future claims. Later in 2023 the payer began reprocessing a significant number of claims that has resulted in denied charges being paid to us. The payment of the reprocessing began in early June 2023 and continued into the current fiscal year. We have paid this liability to the payer as of September 30, 2023.

Profit and Loss

Line 2. The amount reported as Assessments includes all assessments received in the month of September. The assessments are tracked in the accounting system using the procedure code and date of service supplied by the provider's remittance advice. While it is assumed that the provider utilized a vaccine that was purchased by the Department of Health in either the corresponding month or a prior month(s), there are too many variables in the purchasing process, the supply chain, and the utilization driving the remittance to provide certainty.

Line 6. The amount reported as 2% Waste is an estimate that was recorded through a journal entry. This estimate will be refined as we continue to process and track the amount of collectible assessments remaining from each DOH funding request. The amount remaining would likely represent vaccines that were not administered and would be considered waste. This will take several months of data before we are able to provide a more accurate estimate and therefore the 2% Waste estimate will continue to be used for the foreseeable future.

Line 7. The amount reported in September as Price Variance and Denials is the actual total of variances and denials identified through the lockbox transactions processed through RMS.

Line 8. The DOH replenishment is the actual "cost" of the vaccines that are associated with the Assessments received in September.

Line 10. The amount reported as DOH Cost Recovery Admin Charge is the amount requested by the DOH for administrative expenses incurred in August. It was paid with the October 2023 replenishment of vaccines.

Other


Based upon a review of detailed assessment remittance data, the Association at times receives both over- and under-payments for remittances. Overpayments are repaid through the refunds process, through balance forward remittances, or through a separate, specific analysis. These payment discrepancies are found primarily by utilizing the assessment remittance database. Payment discrepancies are primarily caused by incorrectly set up payer adjudication systems or provider dosage-based assessment submission errors.

Key Performance Indicators


Board

November 2, 2023


Beginning and Ending Cash Balances 13 Month Period



Vaccine Collections and Remittances 13 Month Period




FY24 Planned Cash, Actual Cash, and Variance




DOH Projections vs. Actual Remittances

Comparison of DOH Projections with Actual WA DOH Remittances and the % Difference
Rolling 13 Months: November 2022 to November 2023 Funding as of 2023.10.24
Excludes Idaho Assessments




FY24 Administrative Expense Budget to Actual by Month




Total Doses, Total Remittances & Remittance Per Dose by FY

Total Doses, Total Remittances & Remittance Per Dose
Rolling Nine Years: FY2015-FY2024 as of 2023.10.24
Excludes Idaho Assessments / Includes DOH Indirect Rate and Cost Recovery Charge




Non-Flu, Flu, COVID, RSV Doses Purchased by FY

Non-Flu, Flu, COVID, and RSV Doses Purchased by FY
Rolling Nine Years: FY2015 - FY2024 as of 2023.10.24
Excludes Idaho Assessments



DOH Indirect Rate and Cost Recovery Charge by Month



**WASHINGTON VACCINE ASSOCIATION
FINANCIAL STATEMENTS
YEARS ENDED JUNE 30, 2023 AND 2022**



CPAs | CONSULTANTS | WEALTH ADVISORS

CLAconnect.com

Meeting Packet Page 37

**WASHINGTON VACCINE ASSOCIATION
TABLE OF CONTENTS
YEARS ENDED JUNE 30, 2023 AND 2022**

INDEPENDENT AUDITORS' REPORT	1
FINANCIAL STATEMENTS	
STATEMENTS OF FINANCIAL POSITION	3
STATEMENTS OF ACTIVITIES	4
STATEMENTS OF FUNCTIONAL EXPENSES	6
STATEMENTS OF CASH FLOWS	7
NOTES TO FINANCIAL STATEMENTS	8



INDEPENDENT AUDITORS' REPORT

Board of Directors
Washington Vaccine Association
Seattle, Washington

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Washington Vaccine Association (the Association), a Washington nonprofit organization, which comprise the statements of financial position as of June 30, 2023 and 2022, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Washington Vaccine Association as of June 30, 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We are required to be independent of Washington Vaccine Association and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Washington Vaccine Association's ability to continue as a going concern for one year after the date the financial statements are available to be issued.


Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Washington Vaccine Association's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Washington Vaccine Association's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.



CliftonLarsonAllen LLP

Bellevue, Washington
September 14, 2023

**WASHINGTON VACCINE ASSOCIATION
STATEMENTS OF FINANCIAL POSITION
JUNE 30, 2023 AND 2022**

	<u>2023</u>	<u>2022</u>
ASSETS		
CURRENT ASSETS		
Cash and Cash Equivalents	\$ 433,937	\$ 11,101,243
Estimated Collectible Assessments	3,619,709	4,112,039
Prepaid Vaccines to Washington Department of Health	<u>7,623,145</u>	<u>6,845,103</u>
Total Current Assets	11,676,791	22,058,385
INVESTMENTS	<u>44,106,058</u>	<u>43,865,196</u>
Total Assets	<u><u>\$ 55,782,849</u></u>	<u><u>\$ 65,923,581</u></u>
LIABILITIES AND NET ASSETS WITHOUT RESTRICTIONS		
CURRENT LIABILITIES		
Accounts Payable	\$ 793,030	\$ 163,490
ASSESSMENTS COLLECTED IN EXCESS OF VACCINE FUNDING AND ADMINISTRATIVE ACTIVITIES	<u>54,989,819</u>	<u>65,760,091</u>
Total Liabilities	55,782,849	65,923,581
NET ASSETS WITHOUT RESTRICTIONS	<u>-</u>	<u>-</u>
Total Liabilities and Net Assets Without Restrictions	<u><u>\$ 55,782,849</u></u>	<u><u>\$ 65,923,581</u></u>

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION
STATEMENT OF ACTIVITIES
YEAR ENDED JUNE 30, 2023**

	Administrative Activities	Vaccine Funding Activities	Total
CHANGE IN NET ASSETS WITHOUT RESTRICTIONS			
Assessment Activity			
Assessments	\$ (7,952,957)	\$ 84,617,457	\$ 76,664,500
Refunds	(386,619)	-	(386,619)
Waste	(313,124)	-	(313,124)
Denials and Price Variances	(512,601)	-	(512,601)
Cost Recovery Charge	(1,005,917)	-	(1,005,917)
Vaccine Replenishments	-	(83,908,415)	(83,908,415)
Net Assessment Activity	(10,171,218)	709,042	(9,462,176)
Investment Income			
Interest and Dividends	1,221,499	-	1,221,499
Realized Loss on Investments	(77,812)	-	(77,812)
Unrealized Depreciation of Fair Value	(598,388)	-	(598,388)
Total Investment Income	545,299	-	545,299
Less: Investment Expenses	(119,740)	-	(119,740)
Net Investment Income	425,559	-	425,559
Expenses			
Administrative			
Third-Party Administrative Services	1,015,612	-	1,015,612
Executive Director Costs and Related Support	315,798	-	315,798
Provider and Payor Education and Outreach	62,154	-	62,154
Administrative Costs	203,359	-	203,359
Other Discretionary Expenditures	136,732	-	136,732
Total Expenses	1,733,655	-	1,733,655
Total Change in Net Assets Without Restrictions	(11,479,314)	709,042	(10,770,272)
VACCINE FUNDING AND ADMINISTRATIVE ACTIVITIES IN EXCESS OF ASSESSMENTS COLLECTED	11,479,314	(709,042)	10,770,272
CHANGES IN NET ASSETS WITHOUT RESTRICTIONS	-	-	-
Net Assets Without Restrictions - Beginning of Year	-	-	-
NET ASSETS WITHOUT RESTRICTIONS - END OF YEAR	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION
STATEMENT OF ACTIVITIES
YEAR ENDED JUNE 30, 2022**

	Administrative Activities	Vaccine Funding Activities	Total
CHANGE IN NET ASSETS WITHOUT RESTRICTIONS			
Assessment Activity			
Assessments	\$ (6,493,823)	\$ 83,643,996	\$ 77,150,173
Refunds	(446,262)	-	(446,262)
Waste	(908,883)	-	(908,883)
Denials and Price Variances	(185,601)	-	(185,601)
Cost Recovery Charge	(846,903)	-	(846,903)
Vaccine Replenishments	-	(74,989,143)	(74,989,143)
Net Assessment Activity	(8,881,472)	8,654,853	(226,619)
Investment Income			
Interest and Dividends	1,084,916	-	1,084,916
Realized Gain on Investments	5,440	-	5,440
Unrealized Appreciation of Fair Value	(2,844,817)	-	(2,844,817)
Total Investment Income	(1,754,461)	-	(1,754,461)
Less: Investment Expenses	(135,679)	-	(135,679)
Net Investment Income	(1,890,140)	-	(1,890,140)
Expenses			
Administrative			
Third-Party Administrative Services	976,167	-	976,167
Executive Director Costs and Related Support	250,980	-	250,980
Provider and Payor Education and Outreach	63,897	-	63,897
Administrative Costs	164,204	-	164,204
Other Discretionary Expenditures	123,738	-	123,738
Total Expenses	1,578,986	-	1,578,986
Total Change in Net Assets Without Restrictions	(12,350,598)	8,654,853	(3,695,745)
VACCINE FUNDING AND ADMINISTRATIVE ACTIVITIES IN EXCESS OF ASSESSMENTS COLLECTED	12,350,598	(8,654,853)	3,695,745
CHANGES IN NET ASSETS WITHOUT RESTRICTIONS	-	-	-
Net Assets Without Restrictions - Beginning of Year	-	-	-
NET ASSETS WITHOUT RESTRICTIONS - END OF YEAR	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION
STATEMENTS OF FUNCTIONAL EXPENSES
YEARS ENDED JUNE 30, 2023 AND 2022**

	2023		
	Program Services	Management and General	Total
Vaccine Replenishments	\$ 84,914,332	\$ -	\$ 84,914,332
Payroll	-	315,798	315,798
Third-Party Administrative Services	-	1,015,612	1,015,612
Special Projects Services	-	62,154	62,154
Legal and Accounting	-	203,359	203,359
Office	-	136,732	136,732
Total	84,914,332	1,733,655	86,647,987
Less: Expenses Netted Against Revenues on the Statement of Activities			
Vaccine Replenishments	(84,914,332)	-	(84,914,332)
Total Expenses Included in the Expense Section of the Statement of Activities	<u>\$ -</u>	<u>\$ 1,733,655</u>	<u>\$ 1,733,655</u>

	2022		
	Program Services	Management and General	Total
Vaccine Replenishments	\$ 75,836,046	\$ -	\$ 75,836,046
Payroll	-	250,980	250,980
Third-Party Administrative Services	-	976,167	976,167
Special Projects Services	-	63,897	63,897
Legal and Accounting	-	164,204	164,204
Office	-	123,738	123,738
Total	75,836,046	1,578,986	77,415,032
Less: Expenses Netted Against Revenues on the Statement of Activities			
Vaccine Replenishments	(75,836,046)	-	(75,836,046)
Total Expenses Included in the Expense Section of the Statement of Activities	<u>\$ -</u>	<u>\$ 1,578,986</u>	<u>\$ 1,578,986</u>

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION
STATEMENTS OF CASH FLOWS
YEARS ENDED JUNE 30, 2023 AND 2022**

	<u>2023</u>	<u>2022</u>
CASH FLOWS FROM OPERATING ACTIVITIES		
Assessments Collected	\$ 74,938,569	\$ 75,661,814
Cash Remittances to Washington Department of Health for Vaccines	(84,686,457)	(75,784,421)
Administrative Expenses Paid	(1,104,115)	(1,586,729)
Cash Received from Interest and Dividend Income	1,221,499	1,084,916
Cash Paid for Investment Expenses	(119,740)	(135,679)
Net Cash Used by Operating Activities	<u>(9,750,244)</u>	<u>(760,099)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of Investments	(57,576,718)	(20,886,813)
Proceeds from Investment Sales	56,659,656	28,950,217
Net Cash Provided (Used) by Investing Activities	<u>(917,062)</u>	<u>8,063,404</u>
NET CHANGE IN CASH AND CASH EQUIVALENTS	(10,667,306)	7,303,305
Cash and Cash Equivalents - Beginning of Year	<u>11,101,243</u>	<u>3,797,938</u>
CASH AND CASH EQUIVALENTS - END OF YEAR	<u><u>\$ 433,937</u></u>	<u><u>\$ 11,101,243</u></u>
RECONCILIATION OF CHANGE IN NET ASSETS TO NET CASH PROVIDED BY OPERATING ACTIVITIES		
Change in Net Assets	\$ -	\$ -
Adjustments to Reconcile Change in Net Assets to Net Cash (Used) Provided by Operating Activities:		
Realized Gain on Investments	77,812	(5,440)
Unrealized Depreciation of Fair Value	598,388	2,844,817
(Increase) Decrease in:		
Estimated Collectible Assessments	492,330	899,290
Prepaid Vaccines to Washington Department of Health	(778,042)	(795,278)
Increase (Decrease) in:		
Accounts Payable	629,540	(7,743)
Assessments Collected in Excess of Vaccine Funding and Administrative Activities	(10,770,272)	(3,695,745)
Net Cash (Used) Provided by Operating Activities	<u><u>\$ (9,750,244)</u></u>	<u><u>\$ (760,099)</u></u>

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2023 AND 2022**

NOTE 1 NATURE OF ORGANIZATION

Organization and Operations

Since 1990, Washington state has maintained a Universal Childhood Vaccine Program, providing vaccines to all children under age 19. Together with state and federal funding, Washington's program has advanced the widely recognized benefits of universal childhood vaccination. Faced with a scheduled end to state funding in 2010, the Washington state legislature established the Washington Vaccine Association (the Association) and mandated the creation of a universal vaccine purchase account to be able to continue providing state-supplied vaccines to privately-insured children. This legislation was adopted after a year of study by and with broad support from the Washington health care community.

The Association is a special purpose nonprofit corporation formed on April 1, 2010, to support the state government in developing and administering a new method for collecting funds to support the Universal Childhood Vaccine Program. The Washington legislature created the Association through the Washington Vaccine Association Act, now codified in RCW 70.290.010 – .900.

The Association's members are comprised of all health insurance carriers issuing or renewing health benefit plans in Washington state, and all third-party administrators (TPAs) conducting business on behalf of residents of Washington state or Washington health care plans.

The Association's primary purpose is to collect funds through mandatory assessments paid by its members. Fund transfers are made to the state of Washington Department of Health (DOH) on a just-in-time basis for the on-going pre-purchase of vaccines. The vaccines are to be administered to children in the state of Washington who are under the age of 19 and who are not eligible for federal or state funded vaccines through existing programs.

The Association is operated under a Plan of Operation adopted by the board of directors as required by RCW 70.920.030 (5)(b). The Association's governance documents are available at the Association's website: www.wavaccine.org.

Termination of the Association

The Association's board may vote to recommend termination of the Association if it finds that the original intent of its formation and operation has not been achieved. The Association's board must provide notice of the recommendation to the relevant policy and fiscal committees of the Washington state legislature within 30 days of the vote being taken by the Association's board. If the legislature has not acted by the last day of legislative session to reject the board's recommendation, the board may vote to permanently dissolve the Association.

In the event of a voluntary or involuntary dissolution of the Association, funds remaining in the Universal Vaccine Purchase Account (UVPA) created in RCW 43.70.720 must be returned to members in proportion to their previous year's contribution, from any balance remaining.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2023 AND 2022**

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements of the Association have been prepared in accordance with the provisions of accounting standards generally accepted in the United States of America. Under those standards, net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. The Association's net assets do not contain restrictions as of June 30, 2023 and 2022.

Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

For the purposes of the statements of cash flows, all highly liquid investments available for use with an initial maturity of three months or less are considered to be cash equivalents.

Investments

Investments in marketable equity securities, U.S. treasury securities, U.S. federal agencies, corporate bonds, and certificates of deposit with original maturities greater than 90 days are reported at fair value. Realized and unrealized gains and losses are reflected in the statement of activities as changes in net assets without restrictions unless their use is restricted by a donor or by law.

Estimated Collectible Assessments

Estimated collectible assessments represents the running total of replenishment requests to date minus amounts collected to date through the end of the year and is the amount the Association expects to collect from members. Similarly, the Association may receive assessments that are suspected or alleged to be paid in error. In order to provide transparency regarding any credible liability, an estimate of the amount allegedly received in error will be recorded as a liability. The estimate of the liability will be based upon the most credible information available at the time of the event. However, as with all estimates, actual results may differ from the Association's estimate. The Association has determined that an allowance for uncollectible amounts is not necessary due to the method used to calculate the balance.

The Association charges interest on late payment of assessments at a monthly rate of 1.5%. Interest is added to the assessment for payments received after the due date of the assessment.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2023 AND 2022**

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Concentration of Risk

Financial instruments that subject the Association to concentrations of credit risk consist of cash deposits. The Association places its cash deposits with high quality financial institutions. Deposits exceed federally insured limits as of June 30, 2023 and 2022.

Dosage Based Assessments

Funds collected from health insurers and third-party administrators (TPAs) of health plans in the state of Washington, (including administrative revenue and reserve portion discussed below), are determined using a Dosage Based Assessment methodology. At each vaccine administration of a child in the state of Washington, not otherwise eligible for state or federally-funded vaccine programs, the provider's office charges for and generates a claim for administrative services and also generates an item, resembling a claim form, on which the per-vaccine assessment is reported to the respective payor. The per-vaccine assessment amounts are established periodically by the Association. The payor pays the provider for the administration claim, and also pays the assessment amount to the Association, in a manner similar to payment of a claim for the cost of vaccines. The Association collects these assessments and remits payments to the DOH to pay its allocated share of vaccine costs each time a vaccine replenishment order for the State's Universal Childhood Vaccine Program is due. The cost for each vaccine is negotiated by the Center for Communicable Diseases.

Revenue Recognition

Revenue from Exchange Transactions: The Association recognizes revenue in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2014-09, *Revenue from Contracts with Customers*, as amended. ASU 2014-09 applies to exchange transactions with customers that are bound by contracts or similar arrangements and establishes a performance obligation approach to revenue recognition. The Association records the following exchange transaction revenue in its statements of activities for the years ended June 30, 2023 and 2022:

The Association collects member assessments that are remitted to the DOH for purchase of vaccines. In addition, the Plan of Operation allows the Association to retain sufficient funds to cover its administrative costs, net of investment income. Expense is recognized for the administrative costs of operating the Association. The replenishment of vaccines and collection of vaccine assessments are similar to agency transactions. Although these transactions are not considered revenue or expenses of the Association, they are included in the statement of activities as vaccine replenishments to reflect the gross amount of collections and replenishments.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2023 AND 2022**

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Remittance to Universal Vaccine Purchase Account

The Plan of Operation requires the Association to periodically remit its assessment receipts, less the Association's administrative costs and any reserves set by the board or its finance committee, to the credit of the UVPA established pursuant to RCW 43.70.720. Funds transferred to the UVPA are to be delivered on a just-in-time basis, in order to support the assessment collection process. The DOH or its designee has access privileges to be able to directly observe the balances in the Association's accounts, and the Association is required to promptly respond to any inquiry of the DOH concerning the availability and timely transfer of funds, enabling the DOH to make payment of the Association's share under the statute for vaccine purchases made by the state of Washington.

Assessments Collected in Excess of Vaccine Funding and Administrative Costs

The Association has collected assessments in excess of amounts required to be paid to the DOH through the end of the accounting period for childhood vaccine funding and administrative costs. The Association is a limited purpose entity whose funds are dedicated solely to the specific purposes discussed above. These excess assessment collections, which may accumulate from time to time, will be applied to (i) future vaccine funding obligations of the Association, and (ii) reasonable and necessary operating costs of the Association. The Association maintains a level of excess collections (reserves) to be able to meet DOH needs for vaccine purchases and ensure adequate funds for operations. As of June 30, 2023 and 2022, assessments collected in excess of vaccine funding and administrative activities totaled \$54,989,819 and \$65,760,091, respectively.

Income Taxes

The Association follows FASB Accounting Standards Codification (ASC) Topic 740, *Income Taxes (Topic 740)*. Topic 740 clarifies the accounting for uncertainty in income taxes.

The Association operates as a tax-exempt organization created by Washington state statute and as an affiliate of a governmental unit. In order to obtain 501(c)(3) status and to determine whether filing of an annual federal information return (Form 990) is required, the Association prepared and submitted Form 1023 to the Internal Revenue Service (IRS) in June 2012. On May 14, 2013, the IRS granted 501(c)(3) tax-exempt status and determined that the filing of Form 990 is not required in prior or future years.

Management evaluated the Association's tax positions and concluded that the Association had taken no uncertain tax positions that require adjustments to the financial statements. Based upon its evaluation, the Association has concluded that it is operating in compliance within its tax-exempt status and that there are no matters that would create taxable income.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis in the statements of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Vaccine replenishments are considered to be program expenses and all other expenses are administrative.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2023 AND 2022**

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Subsequent Events

The board of directors and management have evaluated subsequent events through September 14, 2023, the date the financial statements were available to be issued.

NOTE 3 INVESTMENTS AND FAIR VALUE MEASUREMENTS

FASB established a framework for measuring fair value and disclosing fair value measurements to financial statement users. Fair value is the price that would be received to sell an asset or paid to transfer a liability (referred to as the exit price) in an orderly transaction between market participants in the principal market, or if none exists, the most advantageous market, for specific assets or liabilities at the measurement dates. The fair value should be based on assumptions that market participants would use, including consideration of nonperformance risk.

In determining fair value, the Association uses various valuation approaches. FASB established a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Association. Unobservable inputs are inputs that reflect the Association's assumptions that market participants would use in pricing the assets or liabilities developed based on the best information available in the circumstances.

The hierarchy is broken down into three levels based on the observability of inputs as follows:

Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets to which the Association has access.

Level 2 – Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in inactive markets; inputs other than quoted market prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The availability of observable inputs can vary and is affected by a wide variety of factors, including, for example, the type of asset or liability, the liquidity of markets, and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Association in determining fair value is greatest for instruments categorized in Level 3.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2023 AND 2022**

NOTE 3 INVESTMENTS AND FAIR VALUE MEASUREMENTS (CONTINUED)

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Fair value is a market-based measure considered from the perspective of a market participant rather than an organization-specific measure. Therefore, even when market assumptions are not readily available, the Association's own assumptions are set to reflect those that the Association believes market participants would use in pricing the asset or liability at the measurement date.

The following table sets forth by level, within the fair value hierarchy, the Association's assets at fair value as of June 30, 2023:

	Level 1	Level 2	Level 3	Total
Money Market Funds	\$ 10,531,861	\$ -	\$ -	\$ 10,531,861
Corporate Bonds	10,955,294	248,930	-	11,204,224
U.S. Treasuries	1,752,643	-	-	1,752,643
U.S. Federal Agencies	3,248,783	9,830,867	-	13,079,650
Certificates of Deposit	-	7,537,680	-	7,537,680
Total Schedule of Investments	<u>\$ 26,488,581</u>	<u>\$ 17,617,477</u>	<u>\$ -</u>	<u>\$ 44,106,058</u>

The following table sets forth by level, within the fair value hierarchy, the Association's assets at fair value as of June 30, 2022:

	Level 1	Level 2	Level 3	Total
Mutual Funds	\$ 1,259,137	\$ -	\$ -	\$ 1,259,137
Corporate Bonds	14,704,825	3,070,824	-	17,775,649
U.S. Treasuries	2,774,229	-	-	2,774,229
U.S. Federal Agencies	10,066,917	2,280,768	-	12,347,685
Certificates of Deposit	-	9,708,496	-	9,708,496
Total Schedule of Investments	<u>\$ 28,805,108</u>	<u>\$ 15,060,088</u>	<u>\$ -</u>	<u>\$ 43,865,196</u>

NOTE 4 REMITTANCE TO THE STATE OF WASHINGTON

Pursuant to the Association's statutory purposes, a transfer of \$84,914,332 and \$75,836,046 was made by the Association to the UVPA during the years ended June 30, 2023 and 2022, respectively. The transfers include a cost recovery administrative charge assessed by the DOH.

**WASHINGTON VACCINE ASSOCIATION
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2023 AND 2022**

NOTE 5 CONTINGENCIES

There is an inherent risk that a certain portion of the vaccines purchased by the DOH will not be administered to children, resulting in vaccine shrinkage. If member assessments are insufficient for reimbursement to the DOH for purchases of vaccines, the Association would be liable to the DOH to cover the shortfall through reserves. The Association's reserves are intended to meet any such contingency.

NOTE 6 INFORMATION REGARDING LIQUIDITY AND AVAILABILITY

The Association is substantially supported by assessment income. As part of the Association's liquidity management, it has a policy to structure its financial assets to be available for its general expenditures, liabilities, and other obligations come due. Financial assets in excess of near-term cash requirements are invested in various marketable securities.

The board of directors of the Association (the Board) has determined that to carry out its statutory and charitable purpose, the Association should maintain minimum reserves in amounts projected by the Board to cover several months of vaccines costs plus the next flu season vaccines to provide liquidity to fund the costs of such vaccines through timely (just in time) deposits to the UVPA.

The following table reflects the Association's financial assets available within one year to meet cash needs for general expenditures as of June 30:

	2023	2022
Cash and Cash Equivalents	\$ 433,937	\$ 11,101,243
Estimated Collectible Assessments	3,619,709	4,112,039
Investments	44,106,058	43,865,196
Total Financial Assets Available to Meet Cash		
Needs for General Expenditures Within One Year	<u>\$ 48,159,704</u>	<u>\$ 59,078,478</u>



CLA (CliftonLarsonAllen LLP) is a network member of CLA Global. See CLAGlobal.com/disclaimer. Investment advisory services are offered through CliftonLarsonAllen Wealth Advisors, LLC, an SEC-registered investment advisor.

Reestablishing Reserve Thresholds

Board

November 2, 2023

Discussion Overview


- ✓ Reserves Have Historically Been Three Months of Vaccines + Influenza
- ✓ Reserve Goal Set in April 2023 = \$30-32M end of FY2025/26
- ✓ September 2023 → COVID-19 Vaccines Were Added to Vaccine Grid
- ✓ October 2023 → Board Approved \$14.3M of Reserves for Nirsevimab
- ❑ Reserve of 3 Months Supply (\$36M) + Influenza (\$4.5M) + (\$5M contingency) = \$45.5M by End of FY2025(?)/26(?)/27(?)

Today's Discussion

Reserve Threshold Considerations

- Consideration of 1, 2, or 3 Years to Rebuild the Reserves
- Lower Expected Bond Portfolio Returns Due to Smaller Portfolio
- Need Additional Reserves for New Vaccines
- Escalating Vaccine Inflation
- WA DOH's COVID-19 Estimates of \$12M/Year
- WA DOH's RSV Nirsevimab Estimates of \$10.2M-20.4M/Year
- Grid Must Remain Below the Private Market Prices

CDC Prices of Recent ACIP Additions




The Case for Reserves

Excluding Beyfortus and Abrysvo, Average of Recent Additions = \$142/Dose

Doses and Costs – Summary

% of Projected Doses and % of Projected Costs* SFY 2024



*Excludes Indirect and Cost Recovery Fees

RSV Projections – Source: WA DOH (09/14/23)

Fund Type Categories	If uptake is 100% of eligible population - number of doses annually	If uptake is 100% of eligible population - cost annually	Assume 70% uptake - number of doses annually	Assume 70% uptake - cost annually	Assume 50% uptake - number of doses annually	Assume 50% uptake - cost annually
Total Estimated: total 0 population plus 2 additional doses for 8-19-month-olds who are immunosuppressed and/or AI/AN.	109,793	\$43,368,108	76,855	\$30,357,676	54,896	\$21,684,054
Breakdown by Fund Source						
VFC (50%)	54,896	\$21,684,054	38,427	\$15,178,838	27,448	\$10,842,027
WVA (47%)	51,603	\$20,383,011	36,122	\$14,268,108**	25,801	\$10,191,505
CHP/CHIP (3%)	3,294	\$1,301,043	2,306	\$910,730	1,647	\$650,522
Total Estimate Cost Annually	109,793	\$43,368,108	76,855	\$30,357,676	54,896	\$21,684,054

**Assumes \$395/dose from CDC Price List. Private Market would be \$495/dose or \$17,880,287.

RSV Assessment Plan

- March 31, 2024 – Expect Legislation In Effect
- July 1, 2024 – IP Facilities and OP Provider Begin DBA Submission
 - WVA Assessment Grid Amount Set Less than Private Market Price
 - Multiple Communications to Providers April – June 2024
 - Will Require Working Group to Determine How IP Facilities Can Comply with DBAs
- NOTE: Parallel Backup Plan for Inpatient Facilities
 - Supplemental Assessment Mechanism if Not All Facilities Can Comply
 - Leverage IIS Platform to Compare Doses Ordered/Used with DBA Data
 - Assess All Payers a Separate “DBA Make Up Rate”

Rebuilding Reserves – Board Directed Options


- Reserve of 3 Months Supply (\$36M) + Influenza (\$4.5M) + (\$5M contingency) = \$45.5M
- Assumes \$14.3M RSV Supply Paid for with Reserves
- Annual Increases Versus Flat Assessment Grid

	FY2023	FY2024	FY2025	FY2026
<u>OPTION 1:</u> Cash Reserves Ending Balance – FY25 ↑<u>30%</u> ; FY26 ↑<u>20%</u>	\$43.6M	\$19.5M	\$40.8	\$47.3M
<u>OPTION 2:</u> Cash Reserves Ending Balance – FY25 ↑<u>25%</u> ; FY26 ↑<u>30%</u>	\$43.6M	\$19.5M	\$35.7M	\$47.2M
<u>OPTION 3:</u> Cash Reserves Ending Balance – FY25 ↑<u>20%</u> ; FY26 ↑<u>40%</u>	\$43.6M	\$19.5M	\$30.6M	\$46.2M

Timeline – Next Grid Approval

Other Milestones:

- Nov 2023 – New DOH Projections
- Apr 2024 – Final DOH Projections



BILL REQUEST - CODE REVISER'S OFFICE

BILL REQ. #: Z-0415.3/24 3rd draft

ATTY/TYPIST: MW:lel

BRIEF DESCRIPTION: Updating the definition of "vaccine" in RCW
70.290.010.

1 AN ACT Relating to updating the definition of "vaccine" in RCW
2 70.290.010; amending RCW 70.290.010; and declaring an emergency.

3 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

4 **Sec. 1.** RCW 70.290.010 and 2010 c 174 s 1 are each amended to
5 read as follows:

6 The definitions in this section apply throughout this chapter
7 unless the context clearly requires otherwise.

8 (1) "Association" means the Washington vaccine association.

9 (2) "Covered lives" means all persons under the age of nineteen
10 in Washington state who are:

11 (a) Covered under an individual or group health benefit plan
12 issued or delivered in Washington state or an individual or group
13 health benefit plan that otherwise provides benefits to Washington
14 residents; or

15 (b) Enrolled in a group health benefit plan administered by a
16 third-party administrator. Persons under the age of nineteen for whom
17 federal funding is used to purchase vaccines or who are enrolled in
18 state purchased health care programs covering low-income children
19 including, but not limited to, apple health for kids under RCW
20 74.09.470 and the basic health plan under chapter 70.47 RCW are not
21 considered "covered lives" under this chapter.

1 (3) "Estimated vaccine cost" means the estimated cost to the
2 state over the course of a state fiscal year for the purchase and
3 distribution of vaccines purchased at the federal discount rate by
4 the department of health.

5 (4) "Health benefit plan" has the same meaning as defined in RCW
6 48.43.005 and also includes health benefit plans administered by a
7 third-party administrator.

8 (5) "Health carrier" has the same meaning as defined in RCW
9 48.43.005.

10 (6) "Secretary" means the secretary of the department of health.

11 (7) "State supplied vaccine" means vaccine purchased by the state
12 department of health for covered lives for whom the state is
13 purchasing vaccine using state funds raised via assessments on health
14 carriers and third-party administrators as provided in this chapter.

15 (8) "Third-party administrator" means any person or entity who,
16 on behalf of a health insurer or health care purchaser, receives or
17 collects charges, contributions, or premiums for, or adjusts or
18 settles claims on or for, residents of Washington state or Washington
19 health care providers and facilities.

20 (9) "Total nonfederal program cost" means the estimated vaccine
21 cost less the amount of federal revenue available to the state for
22 the purchase and distribution of vaccines.

23 (10) "Vaccine" means ~~((a preparation of killed or attenuated~~
24 ~~living microorganisms, or fraction thereof, that upon administration~~
25 ~~stimulates immunity that protects against disease and is))~~ an
26 immunization approved by the federal food and drug administration as
27 safe and effective and recommended by the advisory committee on
28 immunization practices of the centers for disease control and
29 prevention for administration to children under the age of nineteen
30 years.

31 NEW SECTION. **Sec. 2.** This act is necessary for the immediate
32 preservation of the public peace, health, or safety, or support of
33 the state government and its existing public institutions, and takes
34 effect immediately.

--- END ---



Dear Friends and Colleagues,

As I reflect upon this past year's work, I am grateful to all the individuals who have enabled the WVA to become a successful, well-managed non-profit. This past year has been one of growth and development as we prepared for COVID vaccine commercialization and welcomed a new employee tasked with stakeholder relations outreach. As new and more expensive childhood vaccines have been added to the routine immunization schedule, the WVA's role has become increasingly important in ensuring all Washington kids have equal access to these critical vaccines. The last two years' work in stakeholder building and operational precision has increased operational efficiency, allowing the WVA to focus on communication improvements and enhanced provider and payer resources.

The WVA has continued to maintain its reserve targets, and the Board voted to only make a minimal cost adjustment for inflation in assessments after three years of holding the assessment grid steady. The WVA remains fiscally ready to be adaptive as pediatric immunization evolves.

Thank you again to all the individuals and institutions that make universal vaccine purchase for Washington State's children possible.


John Dunn, MD
Board Chairman

Thirteen Years of Stable Vaccine Funding for Washington State Children

The Washington Vaccine Association (WVA) is excited once again to share the important benefits of our state's unique universal Childhood Vaccination Program (CVP).

- **Healthcare Savings.** The DOH's bulk purchases of all pediatric vaccines from the Centers for Disease Control and Prevention's (CDC) manufacturer contracts provide significant cost savings versus private market costs.
- **Stable Vaccine Supply.** Providers can focus on patient needs and have the full complement of recommended vaccines on hand to immunize children.
- **Consolidated Storage and Ordering.** Provider staff can avoid both navigating complex ordering systems and keeping separate storage inventories for vaccines based on insurance status. This allows for a blended stock of vaccines and a streamlined ordering process, supported by the CVP.
- **No Provider Financing Costs.** Instead of fronting significant dollars to keep vaccines on hand, providers receive and administer pediatric vaccines procured by the DOH and use their existing billing system to trigger the WVA's collection of funds from health plans for privately insured children.

BY THE NUMBERS

WVA HAS FUNDED
 **1.17**
MILLION
DOSES OF
VACCINE

 **\$40.3**
MILLION

**SAVED BY WVA
IN VACCINE COSTS**
30% below private
sector costs

VACCINE PURCHASED
USING WVA FUNDS


\$84.64 MILLION



965
PROVIDERS
ENROLLED IN 2022





WVA BOARD OF DIRECTORS

John B. Dunn, MD, MPH, Chair
Medical Director for Preventative Care,
Kaiser Permanente

Beth Harvey, MD, Vice Chair
South Sound Pediatrics

**Edgar Marcuse, MD, MPH, FPIDS,
Secretary**
Emeritus Professor of Pediatrics,
University of Washington

John Soback, MD, MBA, Treasurer
Senior Medical Director,
Regence and Asuris Health Plans
(Cambia Health Solutions)

Helen Chea, MD
Pediatric Medical Director,
Molina Healthcare

Jason A. Farber, Esq.
Partner, Davis Wright Tremaine LLP

Kara Manley
Director, Provider Market Operations,
United Healthcare

Chad Murphy, BS, PharmD
SVP, Chief Clinical Officer,
Premiera Blue Cross

Michele Roberts, MPH, MCHES
Assistant Secretary, Prevention
and Community Health Division,
Washington State Department of Health

Pamela Sheffield, MD
Senior Medical Director, Clinical Solutions,
NW and Mountain, Medical Health Services,
Aetna

WVA STAFF

Julia Walter Zell, MA, Esq.
Executive Director

HELMES & COMPANY, INC. STAFF
Patrick B. Miller, MPH
Administrative Director

P 888.928.2224 | F 888.928.2242
info@wavaccine.org | wavaccine.org

Expanding our support base to improve our response



Cheri Cagle,
Stakeholder Liaison

This year, the WVA welcomed a new employee and Tacoma resident, **Cheri Cagle**, as the **Stakeholder Liaison** of the Washington Vaccine Association. Cheri is a Certified Professional Coder and has worked in a pediatric office setting for over 24 years. Her previous position provided her with the ability to gain proficient knowledge in medical coding, billing, and revenue cycle management. She has experience communicating with insurance companies on various matters such as claim denials, payment edits, contracts, and credentialing.

She will be joining **Lisa White**, **Customer and Financial Support Specialist**, who we've been relying solely upon for the past three years. Lisa White has worked in numerous sectors including healthcare, legal, and education. She has direct experience in customer service, insurance processing, and health information management work, and holds both a Master of Science degree and a Juris Doctorate.

We are excited to expand our support base to improve our response time to stakeholder inquiries and our capacity for proactive and onsite provider trainings. We are confident that with Lisa and Cheri's decades of experience, the WVA will be able to meet the needs of our healthcare partners as the WVA evolves to support Washington's Childhood Vaccination Program.




Lisa White,
Customer and Financial
Support Specialist

FINANCIALS

July 1, 2022 - June 30, 2023


Childhood Vaccine Funding Sources

Estimated Total: \$184,626,596



WVA Program Expenditures

Total: \$84,686,457



Meeting Packet Page 67